Trial · NCT05103332
Participant flow198
How many started, completed or left each group, period by period.
1 to 20 of 198
Download this page as JSON| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| DB Period (6 Months=168 Days) | STARTED | DB Period: Placebo (Add-on to Indapamide) | 65 | |
| DB Period (6 Months=168 Days) | STARTED | DB Period: Zilebesiran (Add-on to Indapamide) | 65 | |
| DB Period (6 Months=168 Days) | STARTED | DB Period: Placebo (Add-on to Amlodipine) | 120 | |
| DB Period (6 Months=168 Days) | STARTED | DB Period: Zilebesiran (Add-on to Amlodipine) | 120 | |
| DB Period (6 Months=168 Days) | STARTED | DB Period: Placebo (Add-on to Olmesartan) | 146 | |
| DB Period (6 Months=168 Days) | STARTED | DB Period: Zilebesiran (Add-on to Olmesartan) | 147 | |
| DB Period (6 Months=168 Days) | STARTED | DB Period (Placebo) to OLE Period (Zilebesiran) [Indapamide Cohort] | 0 | |
| DB Period (6 Months=168 Days) | STARTED | DB Period (Zilebesiran) to OLE Period (Zilebesiran) [Indapamide Cohort] | 0 | |
| DB Period (6 Months=168 Days) | STARTED | DB Period (Placebo) to OLE Period (Zilebesiran) [Amlodipine Cohort] | 0 | |
| DB Period (6 Months=168 Days) | STARTED | DB Period (Zilebesiran) to OLE Period (Zilebesiran) [Amlodipine Cohort] | 0 | |
| DB Period (6 Months=168 Days) | STARTED | DB Period (Placebo) to OLE Period (Zilebesiran) [Olmesartan Cohort] | 0 | |
| DB Period (6 Months=168 Days) | STARTED | DB Period (Zilebesiran) to OLE Period (Zilebesiran) [Olmesartan Cohort] | 0 | |
| DB Period (6 Months=168 Days) | STARTED | DB (Placebo) to SFU or OLE (Zilebesiran) to SFU [Indapamide Cohort] | 0 | |
| DB Period (6 Months=168 Days) | STARTED | DB (Zilebesiran) to SFU or OLE (Zilebesiran) to SFU [Indapamide Cohort] | 0 | |
| DB Period (6 Months=168 Days) | STARTED | DB (Placebo) to SFU or OLE (Zilebesiran) to SFU [Amlodipine Cohort] | 0 | |
| DB Period (6 Months=168 Days) | STARTED | DB (Zilebesiran) to SFU or OLE (Zilebesiran) to SFU [Amlodipine Cohort] | 0 | |
| DB Period (6 Months=168 Days) | STARTED | DB (Placebo) to SFU or OLE (Zilebesiran) to SFU [Olmesartan Cohort] | 0 | |
| DB Period (6 Months=168 Days) | STARTED | DB (Zilebesiran) to SFU or OLE (Zilebesiran) to SFU [Olmesartan Cohort] | 0 | |
| DB Period (6 Months=168 Days) | Modified Full Analysis Set (mFAS) | DB Period: Placebo (Add-on to Indapamide) | 64 | |
| DB Period (6 Months=168 Days) | Modified Full Analysis Set (mFAS) | DB Period: Zilebesiran (Add-on to Indapamide) | 63 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05103332/flow